Assembly Biosciences (NASDAQ:ASMB) Sees Large Volume Increase – Time to Buy?

Assembly Biosciences, Inc. (NASDAQ:ASMB) saw strong trading volume on Monday . 161,257 shares were traded during mid-day trading, an increase of 114% from the previous session’s volume of 75,309 shares.The stock last traded at $36.0560 and had previously closed at $35.26.

Wall Street Analyst Weigh In

Several research firms have issued reports on ASMB. Guggenheim increased their target price on Assembly Biosciences from $31.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday, September 8th. Citizens Jmp initiated coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They issued an “outperform” rating and a $38.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a report on Monday. Mizuho set a $40.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a research note on Thursday, November 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Assembly Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Assembly Biosciences Stock Performance

The stock has a market capitalization of $533.61 million, a P/E ratio of -7.04 and a beta of 1.14. The firm has a 50-day moving average price of $33.63 and a 200 day moving average price of $25.78.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.22). Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%.The firm had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $7.46 million. On average, equities analysts anticipate that Assembly Biosciences, Inc. will post -6.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Assembly Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in ASMB. American Century Companies Inc. bought a new stake in Assembly Biosciences in the first quarter worth $113,000. Acadian Asset Management LLC grew its stake in shares of Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 6,823 shares during the last quarter. Palumbo Wealth Management LLC increased its holdings in shares of Assembly Biosciences by 3.8% in the second quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock worth $338,000 after buying an additional 681 shares during the period. Geode Capital Management LLC lifted its stake in shares of Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after acquiring an additional 3,312 shares during the last quarter. Finally, Ellsworth Advisors LLC purchased a new stake in Assembly Biosciences during the 3rd quarter valued at about $852,000. Institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.